Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24618316 | 0.86 | TAAR1 (0.47) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL29043753 | 0.78 | SLC6A2 (0.50) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL1572105 | 0.78 | SLC6A2 (0.64) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL347187 | 0.78 | SLC6A2 (0.64) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL7455615 | 0.77 | CYP1A2 (0.54) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL24855465 | 0.77 | ESR1 (0.40) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL25808751 | 0.77 | TRPA1 (0.46) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL28358439 | 0.76 | SLC6A2 (0.61) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL4661772 | 0.76 | SLC6A2 (0.61) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| Ammonia Solution, Strong SCHEMBL10608295 | 0.76 | SLC6A2 (0.61) | SLC6A2TAAR1LMNACYP2D6TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120007-B | Antioxidant cement-based waterproof material and preparation process thereof | 安徽朗凯奇科技股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3532642-B1 | DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-06-03 | — | — | US | disclosed |
| EP-3738956-A1 | CXCR2 ANTAGONIST | Medshine Discovery Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | SLC6A2 3315/4885TAAR1 3039/4885LMNA 3874/4885 |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | SLC6A2 1160/4885TAAR1 4669/4885LMNA 2516/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | SLC6A2 1160/4885TAAR1 4669/4885LMNA 2516/4885 |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | SLC6A2 4497/4885TAAR1 1204/4885LMNA 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.